CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Activation of UF Health as a QTC represents an important step in expanding access to ZEVASKYN for patients living with RDEB in Florida and the Southeastern United States,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “UF Health is widely recognized for its leadership in dermatology and multidisciplinary patient care, and we are excited to partner with them to bring this innovative gene therapy to eligible children and adult patients in need.”

“The University of Florida Health is now the sole treatment center for ZEVASKYN across the Southeastern United States. This new gene therapy expands the treatment armamentarium for managing epidermolysis bullosa, with the goal of improving skin healing and patient quality of life,” said Michael Lavery, M.D., Clinical Assistant Professor in the Department of Dermatology at the University of Florida and Director of the University of Florida Epidermolysis Bullosa Multidisciplinary Clinic.

“ZEVASKYN brings together the expertise of our Pediatric Surgery and Burn teams and highlights the collaborative care model that defines UF Health. We are proud to partner with Abeona Therapeutics to expand access to specialized treatment for patients with epidermolysis bullosa,” said Dr. Shawn Larson, M.D., Professor and Chief of the Division of Pediatric Surgery at the University of Florida.

UF Health has already initiated patient identification and onboarding activities and is working with Abeona to support treatment access for eligible patients. For more information about receiving ZEVASKYN treatment at UF Health, contact the UF Health Epidermolysis Bullosa (EB) Clinic in Gainesville by calling (352) 594-1500, or by email at eb-clinic@ufl.edu. For more information, visit: https://dermatology.med.ufl.edu/patient-care/epidermolysis-bullosa-ebclinic/.

For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist™, Abeona’s comprehensive patient support program, visit www.abeonaassist.com, call 1-855-ABEONA-1 (1-855-223-6621) or email MyNavigator@AbeonaAssist.com. Abeona Assist offers personalized support, including helping eligible patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance.

About recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in both copies of the COL7A1 gene, leaving them unable to produce functioning type VII collagen, which is necessary to anchor the dermal and epidermal layers of the skin.

About ZEVASKYN® (prademagene zamikeracel) gene-modified cellular sheets
ZEVASKYN is the first and only autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a severe skin disease caused by a defect in both copies of the COL7A1 gene resulting in the inability to produce functional type VII collagen. Without functional type VII collagen and anchoring fibrils, the skin is fragile and blisters easily, leading to wounds that continually open and close, or fail to heal altogether. Patients often have large open wounds that can lead to serious life-threatening complications. ZEVASKYN incorporates the functional type VII collagen-producing COL7A1 gene into a patient’s own skin cells, ex vivo, using a replication-incompetent retroviral vector to produce functional type VII collagen in treated wounds. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application. For more information, visit www.ZEVASKYN.com.

Indication
ZEVASKYN® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Important Safety Information
Serious allergic reactions to ZEVASKYN can occur. Patients should get medical help right away if they experience symptoms like itching, swelling, hives, difficulty breathing, runny nose, watery eyes, or nausea. In rare cases, a severe reaction called anaphylaxis may happen. There is a potential risk that treatment with ZEVASKYN may contribute to the development of cancer because of how the therapy works. Patients should be monitored for the rest of their lives to check for any signs of cancer.

ZEVASKYN is made using human and animal materials. Although these materials are tested before use, the risk of passing on infections cannot be eliminated. The most common side effects are pain from the procedure and itching.

This is not a complete list of side effects. Patients should call their care team for medical advice about side effects. Side effects may be reported to Abeona at 1-844-888-2236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See full Prescribing Information.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to our ability to maintain existing and obtain additional regulatory approvals of ZEVASKYN® and any future product candidates; our ability to successfully commercialize and market ZEVASKYN® and any future product candidates, if approved, and the timing of any commercialization and marketing efforts; our ability to manufacture sufficient batches of ZEVASKYN® to meet demand; our ability to manufacture ZEVASKYN® batches that meet certain product release specifications that were required by FDA at the time of BLA approval and implemented based on a limited clinical dataset; the FDA’s willingness to revise such release specifications to reflect real-world manufacturing experience; our ability to manufacture from provided biopsy material a ZEVASKYN® batch for which revenue may ultimately be recognized, which depends on such factors as qualified treatment centers obtaining biopsy samples from ZEVASKYN® patients of sufficient quality to act as starting material for manufacturing ZEVASKYN®, patient-to-patient variability in cell growth during the ZEVASKYN® manufacturing process, patient health deterioration in close proximity to ZEVASKYN® treatment such that treatment is no longer possible, and expiration of ZEVASKYN®’s 84-hour shelf-life before surgical application of ZEVASKYN® can be performed; our ability to activate additional qualified treatment centers to administer ZEVASKYN® on patients; the ability of qualified treatment centers to enroll patients for treatment or administer ZEVASKYN® on patients; our ability submit an investigational new drug application for ABO-701 and enroll patients in new clinical trials; our ability to access additional financial resources and/or our financial flexibility to reduce operating expenses if required; our ability to obtain additional equity funding from current or new stockholders; the potential impact of unpredicted changes in the structure and/or administration of the United States government or its agencies; our ability to out-license technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount, and sales of assets; the dilutive effect that raising additional funds by selling additional equity securities would have on the relative equity ownership of our existing investors, including under our existing at-the-market sale agreement; the outcome of any interactions with the FDA or other regulatory agencies relating to any of our products or product candidates; our ability to continue to secure and maintain regulatory designations for our product candidates; our ability to develop manufacturing capabilities compliant with current good manufacturing practices for our product candidates; our ability to manufacture cell and gene therapy products and produce an adequate product supply to support clinical trials and potentially future commercialization; the rate and degree of market acceptance of our product candidates for any indication once approved; our ability to meet our obligations contained in license agreements to which we are party; and macroeconomic uncertainty resulting from changes to U.S. trade policy, including current or future tariffs or other trade restrictions.

CONTACT: Contacts:
Investor and Media:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor:
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

380 Meter Hole Completed at Vumba Central; Core Logging Identifies Silica–Carbonate Alteration, Quartz–Carbonate Veining and Sulfides; Full Hole Sampling Planned

Second Drill Hole Underway as Company Advances Approximately 3,000-Meter 2026 Program

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — One Bullion Ltd. (“One Bullion” or the “Company”) (TSXV: OBUL), a gold exploration company holding complete ownership of three highly prospective exploration projects in Botswana, today announced the completion of diamond drill hole VUDD017 to a final depth of 380 meters at its wholly owned Vumba Gold Project in northeastern Botswana. VUDD017 marks the completion of the first hole of the Company’s approximately 3,000-meter 2026 diamond drilling program, with drilling now underway on the next hole, VUDD018.

The hole tested the Central–Makoba target (VGT-01), a priority exploration area identified through the integration of high-resolution airborne magnetic data, historical drilling, trenching, soil geochemistry and surface sampling. VUDD017 was designed to test the down-dip extension of the interpreted mineralized corridor and generate additional geological and structural data to refine the Company’s exploration model and guide follow-on drilling.

Highlights

  • VUDD017 completed to 380 meters at a collar azimuth of 269° true and a dip of −58°, predominantly using HQ-diameter diamond core.
  • Logging records an amphibolite-dominated sequence with variable foliation and banding, silica–carbonate alteration, quartz–carbonate veins and veinlets, and locally observed sulfides.
  • The Company will sample the full 380-meter hole at nominal one-meter intervals, adjusted to geological contacts, with additional quality-control samples included in submissions to ALS Geochemistry in Johannesburg.
  • Geological and structural observations are being incorporated into the three-dimensional model. Drilling of the second hole, VUDD018, has commenced.

“The completion of VUDD017 represents an important step forward in our 2026 exploration program,” said Adam Berk, Chief Executive Officer of One Bullion. “The core logging has identified veining, alteration and sulfides within the amphibolitic host rocks, providing valuable information to refine our geological model and help guide follow-on drilling. We are now progressing full-hole sampling while drilling continues on VUDD018. The resulting assays will be critical to determining the gold content and evaluating the significance of the geological observations identified in the core.”

No assay results for VUDD017 are available. The geological descriptions in this release are based on visual core logging and do not establish gold grade, mineralized widths or economic mineralization.

VUDD017 — Central–Makoba Anchor Hole
VUDD017 was collared within the Central–Makoba target area to cross the interpreted mineralized corridor, which trends approximately north–south. Collar details and the reported completed depth are set out below.

Hole Easting
(mE)
Northing
(mN)
Elevation
(m)
Azimuth
(true)
Dip Depth
(m)
VUDD017 535,976 7,712,693 1,219 269° −58° 380.0

Coordinates: WGS84 / UTM Zone 35S (EPSG:32735). Azimuth and dip are collar settings; negative dip is below horizontal. Depths are measured downhole.

Preliminary Geological Observations
The hole intersected shallow soil cover and oxidized amphibolitic rock before entering fresh amphibolite at approximately 8.9 meters. The bedrock sequence is predominantly amphibolitic, varying from massive to foliated, schistose and banded, with locally quartz-rich intervals and two narrow intervals logged as metasedimentary rock.

From
(m)
To
(m)
Lithology / Observation
0.00 1.20 Topsoil / soil cover.
1.20 8.86 Amphibolitic rock with near-surface weathering and oxidation.
8.86 108.72 Predominantly fresh amphibolite, variably massive, foliated, schistose and banded; local veining and silica–carbonate alteration.
108.72 109.27 Narrow metasedimentary interval.
109.27 330.60 Predominantly amphibolite with variable foliation, banding and quartz-rich intervals; repeated silica–carbonate alteration and veining.
330.60 333.10 Metasedimentary rock.
333.10 380.00 Amphibolite, locally foliated or quartz-rich, with variable silica–carbonate alteration and veining.

This is a lithological summary, not a table of gold intersections. Listed depths are downhole and do not represent true widths of mineralization. Alteration and sulfides are variably distributed, not continuous across the intervals shown.

Silicification is recorded as both banded and locally pervasive alteration of the host rock, as well as in quartz-bearing veins. Carbonate alteration and quartz–carbonate or calcite veins and veinlets recur at multiple depths, with local chlorite alteration and brecciation.

Visual logging identifies sulfides provisionally as pyrite and arsenopyrite, with some grains of uncertain identity. Sulfides occur locally within veins and altered wall rock and along foliation or banding. Their presence and distribution are not a measure of gold content. Geological observations are being evaluated against the target interpretation; the position, grade and continuity of any gold-bearing zones remain to be determined.

Sampling, Analysis and QA/QC
Core logging, photography, cutting and sampling are progressing at the Company’s secure core facility. Sampling will cover the full 380-meter hole rather than only visibly altered or sulfide-bearing intervals. Half-core samples will be cut with a diamond saw at nominal 1.0-meter intervals, adjusted to lithological and mineralogical contacts. The remaining half-core will be retained for reference. Certified reference materials, blanks and duplicates will be included in the analytical submissions as part of the quality assurance and quality control (“QA/QC”) program.

Samples will be bagged, sealed and transported under chain-of-custody procedures to ALS Laboratories in South Africa, an ISO/IEC 17025-accredited facility that is independent of the Company. Gold analysis is planned by 30-gram fire assay with atomic absorption finish (Au-AA25), together with multi-element analysis by four-acid digestion and ICP-AES (ME-ICP61a). Samples returning more than 10 g/t gold are planned for gravimetric-finish re-assay (Au-GRA21), with any additional checks determined by the technical team and laboratory.

Structural measurements have been collected where reliable core orientation was available. Geological, sampling and survey records will be reconciled in the Company’s database, and assay results and associated QA/QC will be reviewed before results are released. The Company expects initial assays approximately four to six weeks after receipt of the samples by the laboratory, subject to turnaround times and any additional analytical or verification work.

2026 Drilling Program and Next Steps
The approximately 3,000-meter program comprises 10 planned HQ diamond holes across priority structural corridors at Vumba. The program is being executed by Mindea Exploration and Drilling Services (Pty) Ltd., which mobilized in August 2026, and is managed by Joe Van Wyk, Vice President, Exploration.

The program uses a decision-gated approach: initial holes test the geological framework, with subsequent locations and orientations refined using the geological observations, structural measurements and, when available, verified assays. Following completion of VUDD017, drilling has commenced on VUDD018. The Company will continue integrating new information into its three-dimensional model while progressing sampling and laboratory submissions. Interpretation of the Maitengwe airborne geophysical survey continues in parallel to support future targeting.

Cautionary Note Regarding Visual Observations
Visual identification of alteration, sulfides and quartz–carbonate veins is preliminary and is not a substitute for laboratory analysis. These observations do not establish gold grade, gold-bearing interval lengths, continuity or economic significance. No gold assays from VUDD017 are reported in this release. Analytical results will be disclosed following receipt, compilation and verification.

Qualified Person
The scientific and technical information contained in this news release has been reviewed and approved by Rory Kutluoglu, P.Geo., a “Qualified Person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects, who is independent of One Bullion.

About One Bullion
One Bullion Ltd. (TSXV: OBUL) is a Toronto-based gold exploration company focused on advancing high-quality gold assets in Botswana, one of Africa’s most stable and mining-friendly jurisdictions. Established in 2018, the Company controls approximately 8,004 km² of prospective land across three greenstone belt-hosted gold projects, including Vumba, Kraaipan, and Maitengwe. One Bullion’s strategy centers on disciplined, data-driven exploration combining modern geological methods with advanced targeting to identify and test high-priority gold targets while maintaining a commitment to environmental stewardship, community engagement, and long-term value creation for stakeholders.

Forward-Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking information includes statements concerning the scope, sequencing and timing of the Company’s exploration program; completion of core sampling and submission to the laboratory; anticipated analytical methods and assay turnaround; continued drilling; integration of geological, structural and assay data into the three-dimensional model; the location and orientation of subsequent holes; and interpretation and future targeting at Maitengwe. This information is based on management’s current expectations and assumptions, including the availability of funding, personnel, contractors and laboratory capacity; continued access to the projects and maintenance of required permits; the ability to complete sampling and drilling safely; and the suitability of the available geological data for ongoing interpretation. Forward-looking information is subject to risks and uncertainties, including changes in geological interpretations, assay results that do not support visual observations, variable core recovery and sample representativity, drilling or equipment problems, weather and access constraints, permitting delays, laboratory backlogs, additional QA/QC or verification requirements, funding availability and risks associated with operations in Botswana.

Actual results, work programs, costs and timelines may differ materially from those expressed or implied. There is no assurance that further drilling will identify economic mineralization or that the current geological interpretation will be confirmed. Readers should not place undue reliance on forward-looking information. Except as required by applicable law, the Company undertakes no obligation to update or revise it as a result of new information, future events or otherwise.

Cautionary Note Regarding United States Securities Laws
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in a jurisdiction in which such offer, solicitation or sale would be unlawful. The Company’s securities have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons, as defined in Regulation S under the U.S. Securities Act, unless an exemption from registration is available.

Contact Information:
Adam Berk, Chief Executive Officer
OneBullion@KCSA.com

Investor Contact:
KCSA Strategic Communications
Jack Perkins or Valter Pinto
T: 212-896-1254
OneBullion@KCSA.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems.

“Samantha brings more than two decades of commercial leadership experience across oncology diagnostics, precision medicine and laboratory services, with a proven ability to build organizations and drive growth,” said Russell Bradley, President and General Manager of CNSide Diagnostics. “Her leadership comes at an important time as we expand CNSide’s reach and build the commercial foundation for Cerenome’s next phase of growth.”

Samantha most recently served as Vice President, U.S. Head of Client Clinical Operations at Caris Life Sciences, where she held senior leadership roles spanning precision medicine, commercial partnerships and clinical operations. She previously held leadership positions in strategic accounts and business development at Genoptix Medical Laboratory and Laboratory Corporation of America.

Samantha holds a Bachelor of Arts and Sciences degree in Cell and Molecular Biology from Texas Woman’s University.   Her career has centered on advancing precision medicine through strategic partnerships and expanding access to innovative diagnostic technologies across the healthcare system.

“CNSide has the potential to change how CNS cancers are detected and monitored, and Cerenome is uniquely positioned to advance that vision,” said Samantha Fowlkes. “I am excited to join the team and help expand CNSide adoption while building a scalable commercial organization focused on improving care for patients with CNS cancers.”

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. Visit https://www.cerenome.com.

About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, the Company’s anticipated growth in CNSide testing volume and reimbursement, the timing and results of REYOBIQ clinical trials, and expectations as to the Company’s future performance and financial position. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Investor Contact

CORE IR

IR@cerenome.com

Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy®

Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone

Results indicate that ART27.13 may possess the profile of a “metabolic regulator” capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated

SOLANA BEACH, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, obesity, pain, dermatologic, or neurological conditions, today announced remarkable results from a nonclinical study of ART27.13, its oral, once-daily, peripherally selective dual cannabinoid receptor agonist, in the diet-induced obesity model widely used to evaluate GLP-1 and other weight-loss medicines. In the study, ART27.13 administered alone produced weight loss comparable to semaglutide, and ART27.13 in combination with semaglutide approximately doubled the weight loss achieved with either agent alone.

Key Findings

  • Weight loss comparable to semaglutide: In obese mice fed a high-fat diet, ART27.13 as a monotherapy reduced body weight from baseline by approximately 20% over four weeks – essentially mirroring the weight-loss curve of semaglutide.
  • Doubling of weight loss in combination: Obese mice treated with both ART27.13 and semaglutide lost approximately 40% of their baseline body weight – twice the weight loss of either agent alone – bringing them to the body weight of lean, normal-weight animals.
  • Weight lost was predominantly fat: Fat loss was greater in the ART27.13 treated groups (~80 % of the total weight loss was fat for both ART27.13 monotherapy or combination with semaglutide and ~70% with semaglutide monotherapy).
  • Lean body mass and body fat were normalized to lean control animals by ART27.13 or semaglutide to similar extents, and the greatest effects were observed in the combination group of ART27.13 and semaglutide.
  • No effect in lean control animals: ART27.13 had no effect on body weight, fat mass or lean mass in lean mice fed a standard diet. The weight-loss effect of ART27.13 appears to be specific to the obese state.
  • Weight loss maintained as appetite recovered: Food consumption in treated obese animals declined initially and then recovered over the course of the study, while body weight remained at its reduced level.
  • Metabolic parameters were favorable for ART27.13: Other markers of metabolic dysregulation (e.g. liver hypertrophy, cholesterol and glucose handling) were favourable for ART27.13 monotherapy, with the greatest effects shown in the combination with semaglutide.

The findings challenge a long-held assumption in obesity research. For more than two decades, the pharmaceutical industry’s approach to cannabinoid receptors in obesity has focused on blocking the CB1 receptor with antagonists or inverse agonists. Full agonists such as ART27.13 which activate the receptors have largely been avoided. ART27.13 is a highly potent agonist of both the CB1 and CB2 receptors that is designed to act in the body’s peripheral tissues while minimizing effects in the brain. Its ability to produce weight and fat loss in obese animals therefore represents a new and differentiated pharmacology in the field.

“The prevailing dogma has been that CB1 antagonism is required for weight loss, so observing semaglutide-like weight loss with a cannabinoid receptor agonist is striking,” observed Andrew Yates, Ph.D., Senior Vice President and Chief Scientific Officer of Artelo. “What makes these data especially compelling is the selectivity. In obese animals, ART27.13 drove substantial fat loss and improved body composition, while in lean animals there was no observed effect on weight, appetite or body composition. That is precisely the profile one would want in an obesity therapeutic.”

The results are consistent with independent, peer-reviewed research showing that both THC and synthetic cannabinoid receptor agonists can reduce body weight and fat in obese animals while having no effect on body weight or metabolic parameters in lean animals1,2. The Artelo data extend those observations to a clinical-stage, orally administered small molecule, with an effect size comparable to the leading GLP-1 medicine.

“The consistency of these results across the initial pilot study and the follow-on study and in every measure we examined – body weight, food consumption, body composition and other metabolic parameters – is what gives us confidence in the signal,” said Professor Saoirse O’Sullivan, Ph.D., Vice President of Translational Science at Artelo. “In this nonclinical model, the doubling of weight loss in combination with semaglutide suggests that ART27.13 may work through a mechanism that is complementary to, rather than overlapping with, GLP-1 receptor agonism. Taken together, we believe the clinical and nonclinical data suggest ART27.13 may act as a peripheral metabolic regulator, promoting weight gain in a wasting state and weight loss in an obese state.”

“Based upon prior published research demonstrating ART27.13 ability to protect against cancer-induced skeletal muscle cachexia, we set out to answer a narrow question – whether ART27.13 could help protect muscle in patients taking GLP-1 medicines – and the study provided insight for a much bigger one,” added Gregory Gorgas, President and Chief Executive Officer of Artelo. “ART27.13 appears to have a profile that may fill a gap in weight-loss strategies. In the context of a global GLP-1 market that J.P. Morgan has projected could reach $200 billion by 2030, and an industry racing toward oral options and combination regimens, we believe these results warrant further investigation as to the role ART27.13 may play within one of the most important therapeutic categories in medicine. In addition to our ongoing partnering initiatives, this new data with ART27.13 is expected to open up new partnering conversations with pharmaceutical companies active in metabolic disease.”

About ART27.13
Initially developed by AstraZeneca plc, ART27.13 is a dual cannabinoid agonist that has been in over seven clinical studies with nearly 300 participants. It is being developed as a once-daily, orally administered agent selectively targeting peripheral CB1 and CB2 receptors, enabling systemic metabolic effects while minimizing central nervous system-mediated toxicity. Artelo is conducting a Phase 2 trial named the Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Interim Phase 2 data revealed patients who had lost at least 5% of body weight to be included in CAReS and titrated to the highest ART27.13 dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while patients on placebo lost an additional ~5%. Currently, there is no FDA approved treatment for cancer anorexia cachexia syndrome. In addition to CAReS, ART27.13 is also being evaluated in a Phase 2 study in people with glaucoma, called the DREAM study, investigating whether oral daily treatment can lower intraocular pressure.

About the Diet-Induced Obesity (DIO) Model
The DIO-2 study evaluated ART27.13 in mice with diet-induced obesity, the standard nonclinical model used across the industry to evaluate GLP-1 receptor agonists and other anti-obesity therapies. Obese mice maintained on a high-fat diet were treated with vehicle, semaglutide (20 nmol/kg) s.c., ART27.13 (2.5 µmol/kg) orally, or semaglutide in combination with ART27.13 under three dosing regimens. Lean mice maintained on standard chow were treated with vehicle or ART27.13 to assess effects in non-obese animals. Body weight and food consumption were measured throughout the four-week treatment period, and body composition was assessed by DEXA and MRI imaging. The findings replicate and extend the results of an initial pilot study (DIO-1) in the same model, in which co-treatment with ART27.13 was observed to improve the weight-loss efficacy when used in combination with semaglutide.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Artelo Biosciences is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in obesity, anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that results observed in nonclinical animal models may not be predictive of, or replicated in, human clinical trials; the preliminary nature of the study results described in this press release, which remain subject to completion of the full analysis; the early stage of our obesity research program; the uncertainty of patent protection and the potential for intellectual property challenges; the highly competitive nature of the pharmaceutical industry, including the GLP-1, obesity and combination therapy markets; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; and our ability to enter into partnering or licensing arrangements on acceptable terms, or at all. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

______________________
1 Avalos, B., Olmos, M., Wood, C.P., Alvarez, C., Read, H.M., Udompholkul, P., Garland, T., Jr and DiPatrizio, N.V. (2026), Δ9 Tetrahydrocannabinol and cannabis extracts differentially improve adipoinsular dysfunction in diet-induced obesity. J Physiol.
2 Verty AN, Stefanidis A, McAinch AJ, Hryciw DH, Oldfield B. (2015) Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice. PLoS One.

GREENWOOD VILLAGE, Colo., Sept. 16, 2026 (GLOBE NEWSWIRE) — Arq, Inc. (NASDAQ: ARQ) (the “Company” or “Arq”), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced that Company management will attend the following upcoming investor conferences:

Gabelli 4th Annual PFAS Symposium

Water Tower Virtual Investor Conference

For interest in scheduling in-person New York meetings with the Arq management team the week of September 21, 2026, please contact investors@arq.com. The presentation materials to be used by Arq management during these upcoming events will be made available prior to the events on Arq’s investor relations website at https://ir.arq.com/.

About Arq

Arq (NASDAQ: ARQ) is a diversified, environmental technology company with products that enable a cleaner and safer planet while actively reducing our environmental impact. As the only vertically integrated producer of activated carbon products in North America, we deliver a reliable domestic supply of innovative, hard-to-source, high-demand products. We apply our extensive expertise to develop groundbreaking solutions to remove harmful chemicals and pollutants from water, land and air. Learn more at: www.arq.com.

Source: Arq, Inc.

Investor Contact:
Anthony Nathan, Arq
Marc Silverberg, ICR
investors@arq.com

NEW YORK, Sept. 16, 2026 (GLOBE NEWSWIRE) — Blockfusion USA, Inc. (“Blockfusion” or the “Company”), a developer and operator of high-performance computing and AI infrastructure, today announced that its wholly owned subsidiary, North East Data, LLC, has entered into a definitive anchor lease (the “Lease”) with CoreWeave, Inc. (“CoreWeave”) (Nasdaq: CRWV), The Essential Cloud for AI™, for capacity at Blockfusion’s Niagara Falls, New York campus, together with a companion expansion agreement (the “Expansion Agreement”). The Lease and the Expansion Agreement convert the non-binding letter of intent announced on June 30, 2026, into definitive agreements.

The Lease has a 15-year initial term with two five-year renewal options.

Blockfusion has transformed a decommissioned power plant into a low-carbon data center powered predominantly by hydroelectric power, and is now adapting the campus for high-density, liquid-cooled AI infrastructure. The site benefits from an existing grid interconnection, clean energy and redundant fiber infrastructure.

“This agreement is a defining milestone for Blockfusion, and strong validation of our Niagara Falls campus,” said Alex Martini-Lo Manto, Chief Executive Officer of Blockfusion. “We are transforming a former industrial site into infrastructure for the next generation of computing and what we believe can become a long-term technology and economic anchor for the region.”

“The conversation about data centers is ultimately about ensuring technology investment translates into real benefits for local communities,” said Robert Restaino, Mayor of the City of Niagara Falls. “Blockfusion’s commitment to Niagara Falls creates opportunities for residents, businesses and future generations. We are encouraged by investments that help strengthen our local economy and position Niagara Falls for long term growth.”

The agreements also mark an important step in Blockfusion’s proposed business combination (the “Business Combination”) with Blue Acquisition Corp. (“Blue”) (Nasdaq: BACC). Subject to closing conditions, the Business Combination is expected to result in Blockfusion Digital Infrastructure, Inc. (“Pubco”) becoming a publicly traded company listed on the Nasdaq Stock Market under the ticker symbol “BDI”. Additional information regarding the Lease, the Expansion Agreement and related arrangements will be included in an amendment to the registration statement on Form S-4 (as amended, the “Registration Statement”) to be filed by Pubco and Blockfusion with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Business Combination.

About Blockfusion

Blockfusion is a developer and operator of predominantly zero-carbon high-performance computing (HPC) and AI infrastructure, delivering scalable, energy-efficient compute capacity to enterprises, government and technology customers. Its flagship campus in Niagara Falls, New York, sources power from low-cost hydroelectric and nuclear generation in NYISO Zone A and benefits from a large-scale grid interconnection. To learn more, visit blockfusion.com, or obtain free copies of documents containing information about Blockfusion at www.sec.gov or by directing a request to Blockfusion at 447 Broadway, 2nd Floor, #538, New York, NY 10013.

Advisors

Howard Berry and Chris Pedersen of Avison Young’s National Data Center Solutions team represented Blockfusion in negotiating the lease transaction. Jones Day served as lead outside counsel to Blockfusion on the Lease related matters. Winston Taylor LLP is serving as legal advisor to Blockfusion. Phillips Lytle LLP is serving as lease, construction, environmental and New York regulatory counsel. The JBernstein Group, LLC is serving as the investor relations advisor on the transaction.

Important Information About the Proposed Business Combination and Where to Find It

Consummation of the proposed business combination transaction that is the subject of the Business Combination Agreement entered into by Blue and Blockfusion in November 2025, as amended, and as may be further amended, amended and restated or supplemented from time to time, remains subject to closing conditions customary for similar transactions, including satisfaction of minimum cash requirements at closing, approval by Blue’s and Blockfusion’s shareholders and the satisfaction of applicable regulatory and exchange listing requirements. Additional information about the proposed transaction can be found in Blue’s public filings and the Registration Statement filed by Pubco and Blockfusion with the SEC in connection with the proposed Business Combination, copies of which can be obtained free of charge from the SEC’s website at www.sec.gov.

The Registration Statement includes a preliminary proxy statement of Blue and a prospectus (the “Proxy Statement/Prospectus”) in connection with the Business Combination to be effected subject to and in accordance with the terms of the Business Combination Agreement. After the Registration Statement is declared effective, the definitive proxy statement and other relevant documents will be mailed to shareholders of Blue as of a record date to be established for voting on the Business Combination and other matters as described in the Proxy Statement/Prospectus. Blue and/or Pubco will also file other documents regarding the Business Combination with the SEC. This communication does not contain all of the information that should be considered concerning the Business Combination and other matters and is not intended to form the basis of any investment decision or any other decision in respect of such matters. Blockfusion, Blue and Pubco may also file other documents with the SEC regarding the Business Combination. Upon closing, Pubco is expected to be a publicly traded, pure-play HPC and AI infrastructure platform.

BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, SHAREHOLDERS OF BLUE AND OTHER INTERESTED PARTIES ARE URGED TO READ, CAREFULLY AND IN THEIR ENTIRETY, THE PRELIMINARY PROXY STATEMENT/PROSPECTUS, AND ANY AMENDMENTS THERETO, AND, WHEN AVAILABLE, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH BLUE’S SOLICITATION OF PROXIES FOR THE EXTRAORDINARY GENERAL MEETING OF ITS SHAREHOLDERS TO BE HELD TO APPROVE THE BUSINESS COMBINATION AND OTHER MATTERS AS DESCRIBED IN THE PROXY STATEMENT/PROSPECTUS BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT BLUE, BLOCKFUSION, PUBCO AND THE BUSINESS COMBINATION.

Past performance by Blockfusion’s or Blue’s management teams and their respective affiliates is not a guarantee of future performance. Therefore, you should not place undue reliance on the historical record of the performance of Blockfusion’s or Blue’s management teams or businesses associated with them as indicative of future performance of an investment or the returns that Blockfusion, Blue or Pubco will, or are likely to, generate going forward.

Investors and security holders will be able to obtain copies of the Registration Statement, the Proxy Statement/Prospectus and all other documents filed or that will be filed with the SEC by Blue and Pubco, without charge, once available, on the SEC’s website at www.sec.gov, or upon written request to: Blue Acquisition Corp., 1601 Anita Lane, Newport Beach, CA 92660; or to Blockfusion USA, Inc. at 447 Broadway, 2nd Floor, #538, New York, NY 10013, respectively.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE BUSINESS COMBINATION DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Participants in the Solicitation

Blue, Blockfusion, Pubco and their respective directors, executive officers, certain equity holders and other members of management and employees may be deemed under SEC rules to be participants in the solicitation of proxies from Blue’s shareholders in connection with the Business Combination. A list of the names of such persons, and information regarding their interests in the Business Combination and their ownership of Blue’s securities are, or will be, contained in Blue’s filings with the SEC, including the final prospectus for Blue’s initial public offering filed with the SEC on June 12, 2025 (the “IPO Prospectus”). Additional information regarding the interests of the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Blue’s shareholders in connection with the Business Combination, including the names and interests of Blockfusion’s and Pubco’s respective directors or managers and executive officers, will be set forth in the Registration Statement and Proxy Statement/Prospectus when available. Investors and security holders may obtain free copies of these documents as described above.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the U.S. federal securities laws. These statements include, but are not limited to, statements regarding the Business Combination and associated potential financing and Company commercial transactions, including expectations, hopes, beliefs, intentions, strategies, plans, prospects, estimates and projected financial and operating results; the anticipated benefits and timing of consummation, if any, of the proposed Business Combination; performance by the parties to the Lease and the capacity, term, timing of delivery and economics thereof; the Expansion Agreement and the conditions to, and availability of, expansion capacity thereunder; estimated contracted Lease revenue; the availability and allocation of additional power and the receipt of necessary permits and approvals related to the Niagara Falls campus and the Company’s expansion and build-out plans; the negotiation and execution of definitive agreements relating to the Company’s anticipated debt and equity financings, and the funding and closing of such transactions; the Company’s prospective post-closing capital expenditures and associated financing plans and activities; the Company’s land acquisition initiatives; expected development capacity, including MW development targets; the anticipated receipt by the Company of sufficient capital to fund the Company’s development plans, subject to identification of additional financing sources, and the terms of any such financing transactions; the assets that may be held by Blockfusion and Pubco after the closing and estimated value thereof; Pubco’s listing on any securities exchange at and following the closing; the satisfaction of closing conditions to the Business Combination and the level of redemptions of Blue’s public shareholders in connection with the closing; and the transaction parties’ expectations, intentions, strategies, assumptions or beliefs about future events, results of operations or performance. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “pathway,” “potential,” “plan,” “may,” “should,” “target,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean a statement is not forward-looking.

Forward-looking statements are predictions, projections and other statements about future events or conditions that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results to differ materially from the forward-looking statements in this communication, including, but not limited to: the risk that the Business Combination may not be completed in a timely manner or at all; the fact that anticipated proceeds to Pubco and Blockfusion from the Business Combination and associated potential financing transactions may be different from current expectations; the risk that actual future revenue derived from the Lease may differ from Company management’s current expectations relative to timelines, aggregate or incremental amounts, lease extensions, IT load expansions and otherwise; the risk that CoreWeave does not perform its obligations under the Lease, that conditions to capacity delivery are not satisfied, or that the Lease is amended or terminated; the risk that the Company does not deliver contemplated capacity on the anticipated timeline or at all, and the consequences under the Lease of any such failure, including termination rights and service level remedies; the risk that some or all of the currently contemplated financing transactions may not be consummated in a timely manner or at all, and, if completed, may be on terms different from the terms reflected in non-binding term sheets and that remain subject to entry into definitive documentation; the risk that the conditions to CoreWeave’s obligation to lease the expansion capacity contemplated under the Expansion Agreement, including the procurement of firm power commitments and CoreWeave’s approval of the power infrastructure plan, may not be satisfied, that CoreWeave may withhold such approval, that no lease for such capacity may be executed and no take-or-pay obligation may arise, and that the commitment period under the Expansion Agreement may expire with capacity unleased; the risk that CoreWeave does not elect to lease any portion of any additional expansion capacity, as to which it has no obligation; the risk that the Company’s anticipated expansion plans may not be achieved within the anticipated timelines or at all; the risk that the Company will not be able to secure the quantum of supplemental financing required to fulfill its business plans and the requirements of anchor and other lease tenants, or that, if such funding is available, it will not be on terms acceptable to Blockfusion; the dilutive effect of any equity or equity-linked securities the Company or Pubco may issue; the risk that changes in New York State energy and environmental policy, including Executive Order 62 and any successor or related measures affecting permitting for data centers, may impact the achievement of MW capacity targets or the timing or cost of the Company’s development plans; the risk that energy infrastructure regulations, interconnection processes or utility tariffs and charges may impact the achievement of MW capacity targets or the Company’s cost of power; the competitive landscape for AI and HPC infrastructure and technological developments; risks related to the Company’s ability to obtain required permits, approvals and interconnection on the anticipated timeline; construction, development, supply-chain and cost risks; risks associated with the acquisition, environmental condition and remediation of land the Company may acquire; failure of the parties to satisfy the closing conditions to the Business Combination (including the approval of Blue’s shareholders); the level of redemptions of Blue’s public shareholders; the failure of Pubco to obtain or maintain the listing of its securities on any securities exchange after the closing of the Business Combination; and changes in business, market, financial, political and regulatory conditions or the availability and pricing of power, among other risks.

The foregoing list of risk factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of Blue’s IPO Prospectus, Blue’s quarterly and annual public filings, the Registration Statement, including the proxy statement/prospectus contained therein, and other documents that have been or will be filed by Blue, Blockfusion and Pubco from time to time with the SEC. These filings do or will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from statements contained in this and other communications by Blue and Blockfusion. There may be additional risks that neither Blue nor Blockfusion presently know or that Blue or Blockfusion currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

Forward-looking statements speak only as of the date they are made. Due to the inherent risks and uncertainties associated with forward-looking statements, readers are cautioned not to put undue reliance on forward-looking statements, and none of Blue, Blockfusion or Pubco assumes any obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of Blue, Blockfusion or Pubco gives any assurance that any of Blue, Blockfusion or Pubco will achieve results consistent with management’s current expectations and beliefs. The inclusion of any statement in this communication does not constitute an admission by Blue, Blockfusion, Pubco or any other person that the events or circumstances described in such statement are material.

No Offer or Solicitation

This press release and the information contained herein is for informational purposes only and is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transactions and shall not constitute an offer to sell or exchange, or a solicitation of an offer to buy or exchange the securities of Blue, Blockfusion or Pubco, or any commodity or instrument or related derivative of Blue or Pubco, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, sale or exchange would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended (the “Securities Act”) or an exemption therefrom. Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the Securities Act.

Contacts

Investor Relations and Media:

Jeff Bernstein

The JBernstein Group

jeffrey@jbgcapadvisory.com

Platform continues to advance integrated capabilities, scenario adaptability and enterprise deployment readiness to support potential scaled commercial applications

SHENZHEN, China, Sept. 16, 2026 (GLOBE NEWSWIRE) — Jiuzi Holdings, Inc. (Nasdaq: JZXN) (“Jiuzi” or the “Company”) today provided an update on the latest progress of its AI intelligent imaging and data platform. Following the Company’s previously announced development roadmap and commercial deployment preparations, Jiuzi is continuing to advance platform-level capability integration, system stability evaluation, scenario adaptability and enterprise deployment readiness, with the objective of supporting the evolution of its AI intelligent imaging technology from individual functional modules toward a more integrated enterprise-level solution.

The Company stated that its current focus is expanding from the development of individual AI recognition capabilities toward system-level coordination and practical scenario adaptability. Around core capabilities including real-time image recognition, dynamic scene analysis, automated content tagging, intelligent image filtering, multimodal data fusion and cloud-based data processing, Jiuzi is continuing to optimize coordination among different platform modules and evaluate the platform’s adaptability under multi-scenario, high-concurrency and continuous-operation conditions.

Jiuzi believes enterprise demand for AI intelligent imaging technology is gradually shifting from isolated algorithm capabilities toward more complete platform-based solutions. For practical commercial deployment, the Company believes that system stability, data-processing efficiency, cross-scenario adaptability, deployment flexibility and compatibility with existing enterprise IT systems are increasingly important alongside algorithmic accuracy.

In response to these trends, the Company is continuing to refine the overall architecture of its AI intelligent imaging platform and is currently advancing work in the following areas:

  ● Platform-level capability integration: continuing to integrate image recognition, scene understanding, data processing and decision-support modules to improve coordination across platform functions.
     
  ● Multi-scenario adaptability evaluation: assessing the platform’s ability to support image acquisition, real-time analysis and data processing across different enterprise operating environments.
     
  ● Multimodal data processing: further integrating video, image and structured data to support more complex enterprise intelligent-analysis applications.
     
  ● System stability and scalability: continuing to evaluate platform performance under high-concurrency, real-time processing and extended-operation conditions in preparation for potential larger-scale deployment.
     
  ● Enterprise deployment readiness: optimizing standardized interfaces, deployment workflows and solution architecture with the goal of reducing future integration and adaptation costs across different customer environments.
     
  ● Commercial application evaluation: continuing to assess potential applications in enterprise operations, security management, content analysis, digital management and other intelligent imaging scenarios.

Through these efforts, the Company is seeking to further develop the AI intelligent imaging platform from a collection of technical capabilities into a more unified, modular and deployable platform architecture. Jiuzi intends to improve the platform’s practical usability in enterprise environments through continued technical evaluation and scenario assessment, while establishing a clearer technical foundation for potential future commercial deployment.

At the same time, the Company continues to evaluate demand for AI intelligent imaging solutions across different industry scenarios. As enterprise data volumes continue to increase and video, image and structured data become more important to business operations, Jiuzi believes that platform-based AI solutions capable of supporting real-time perception, data analytics and business decision support may have broader application potential.

The Company plans to continue developing its AI intelligent imaging business through a phased and prudent approach. As platform maturity, scenario adaptability and commercial models continue to be evaluated, Jiuzi expects to assess additional opportunities for project deployment and commercial cooperation with technology partners, enterprise customers and other ecosystem participants.

The Company emphasized that the relevant work remains in ongoing development, evaluation and commercial deployment preparation stages. The ultimate scale of deployment, customer adoption and commercial contribution, if any, will depend on technical progress, market demand, partner execution, project implementation and other commercial factors.

Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements regarding the development and evaluation of the Company’s AI intelligent imaging and data platform, system validation, scenario adaptability, commercial deployment plans, potential market opportunities and future business development.

Forward-looking statements generally include words such as “believe,” “expect,” “plan,” “may,” “intend” and “will.” These statements are based on the Company’s current judgments and expectations and involve risks and uncertainties that could cause actual results to differ materially from expectations. The Company cannot assure that platform development, technical validation, commercial deployment, customer adoption or anticipated commercial benefits will be achieved as planned. Actual results may differ materially due to technology development progress, market demand, commercial cooperation, competitive conditions, regulatory developments and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

Except as required by applicable law, the Company undertakes no obligation to update any forward-looking statements.

Contact

coco@jzxn.com

Following last week’s signing of the declaration for a 100-Year Partnership and the Joint Declaration on Enhancement of the Defence and Security Cooperation between Ukraine and Canada, Calian and SkyFall are building on renewed defence cooperation to advance allied unmanned systems training and operational readiness.

OTTAWA, Ontario, Sept. 16, 2026 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space and other critical infrastructure sectors, and SkyFall, a leading Ukrainian technology and defence company specializing in the development and large-scale production of high-performance unmanned systems, today announced a strategic partnership to advance unmanned systems training and operational readiness for Canada, the United Kingdom (UK), NATO and allied forces.

The partnership will bring together SkyFall Academy, a training centre certified by the Ministry of Defence of Ukraine with specialized capabilities in unmanned systems training, and Calian’s global capabilities in military training, education, simulation and mission readiness backed by more than four decades of experience designing and delivering complex training programs for the Canadian Armed Forces, the British Army, NATO and allied forces.

Through the partnership, SkyFall and Calian will jointly develop and deliver unmanned systems training and education programs for the armed forces of Canada and the United Kingdom, NATO members and allied nations. The collaboration will facilitate a two-way exchange of experience. SkyFall will contribute its technological, operational and training capabilities while Calian will apply its expertise in designing, integrating and delivering international military training, simulation and large-scale readiness programs within NATO-aligned frameworks. Together, these capabilities will help ensure that training programs reflect current operational realities and rapidly evolving unmanned technologies. 

The collaboration will also support the international expansion of SkyFall Academy and its capacity to deliver specialized training to military personnel, instructors and technical specialists in partner countries. For Calian, the partnership will strengthen its global defence training portfolio by integrating current operational knowledge of unmanned systems into its training, simulation and mission-readiness solutions. Together, these efforts will contribute to closer interoperability between Ukraine, NATO and allied forces.

SkyFall Academy has trained more than 30,000 Ukrainian military personnel over the past three years. Over more than four decades, Calian has trained more than 300,000 personnel in support of the Canadian Armed Forces, the British Army, NATO and allied forces.

“Ukraine has demonstrated the speed at which unmanned systems, tactics and countermeasures can evolve in modern conflict,” said Patrick Houston, CEO, Calian. “As a long-standing training partner to the Canadian Armed Forces and a provider of training support to the British Army, NATO and allied forces, our responsibility is to ensure the training expertise we bring continues to evolve with the operational environment. Learning directly from SkyFall’s experience in Ukraine will strengthen the expertise of our instructors and help ensure military personnel are prepared for the realities of modern operations.”

“This partnership brings together complementary capabilities,” said Mykola Makovieiev, Director of SkyFall. “We combine in-house research and development, engineering, large-scale manufacturing and specialized training, while Calian brings more than 40 years of military training experience and an established international training infrastructure. Together, we will develop joint programs designed to keep pace with the rapidly evolving role of unmanned technologies in modern warfare. For Ukraine, this partnership expands access to NATO-aligned training standards and allied infrastructure, strengthens interoperability with partner nations and supports the deeper integration of Ukrainian technological and training capabilities into the global defence ecosystem.”

About Calian

www.calian.com

For over 40 years, Calian has delivered mission-critical solutions when failure is not an option. Trusted worldwide, we empower organizations in critical industries to overcome obstacles, manage risks and drive progress. By combining the expertise of our people, proven industry insight, cutting-edge technology, bold innovation, and global reach, we deliver tailored solutions that solve complex challenges. Headquartered in Ottawa, Canada, with over 6,000 people around the world, Calian’s solutions protect lives, strengthen security, foster global connectivity and drive economic progress, making a lasting impact where and when it matters most.

Product or service names mentioned herein may be the trademarks of their respective owners.

Media inquiries:
media@calian.com
613-599-8600

Investor Relations inquiries:
ir@calian.com

About SkyFall

As a developer and large-scale manufacturer of unmanned systems, SkyFall operates across the entire technology lifecycle, combining in-house R&D and engineering with production at scale, operational use, continuous product improvement and specialized training. This integrated approach also underpins the training programs delivered through SkyFall Academy.

Key products in SkyFall’s portfolio include the Vampire heavy bomber, Shrike FPV drones, the P1-SUN interceptor, deep-strike, mid-strike and short-strike unmanned systems, communications systems and critical components. These systems are deployed at scale by Ukraine’s Defence Forces and have demonstrated their effectiveness in complex and contested environments. SkyFall systems have helped Ukrainian defenders neutralize enemy personnel and destroy tens of billions of dollars’ worth of enemy equipment.

Media inquiries:
External Relations and Communications Department
media@skyfall.ua

SkyFall on X:
https://x.com/skyfallua

CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), a commercial mortgage real estate investment trust, announced that its board of directors has declared a regular quarterly cash dividend of $0.47 per share for the third quarter of 2026. The regular quarterly dividend, which equates to an annualized rate of $1.88 per common share, is payable on October 15, 2026, to shareholders of record as of the close of business on September 30, 2026.

About Chicago Atlantic Real Estate Finance, Inc.
Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) is a market-leading commercial mortgage REIT utilizing significant real estate, credit and cannabis expertise to originate senior secured loans primarily to state-licensed cannabis operators in limited-license states in the United States. REFI is part of the Chicago Atlantic platform, which has offices in Chicago, Miami, New York, and London.

Contact: 
Tripp Sullivan
Lisa Kampf
SCR Partners
IR@REFI.reit

Program Exceeds Planned Meterage; JN26-003 Submitted for Rush Assay

Vancouver, BC, Sept. 16, 2026 (GLOBE NEWSWIRE) — Aben Gold Corp. (TSX-V: ABM) (OTCID: ABNAF) (Frankfurt: ML1) (“Aben” or “the Company”) is pleased to announce the completion of the 2026 diamond drill program at its 100%-owned Justin Gold-Tungsten Project in southeastern Yukon Territory, approximately 25 kilometres from the past-producing Cantung Mine.
As of September 13, 2026, the Company has completed 1,390.9 metres of diamond drilling in eight holes over 36 operating days. The program exceeded the original plan of approximately 1,300 metres in six holes. A total of 1,464 samples have been collected and shipped to Bureau Veritas and Actlabs for analytical work.

Program Summary

Drilling tested both priority target areas: the POW Zone gold-tungsten system and the Lost Ace high-grade gold target.

Hole ID Zone Start Complete Final Depth (m) Samples*
JN26-001 POW Aug 8 Aug 13 265.30 341
JN26-002 POW Aug 13 Aug 21 207.35 227
JN26-003 POW Aug 21 Aug 29 250.05 217
JN26-004 POW Aug 29 Sep 4 263.30 241
JN26-005 Lost Ace Sep 4 Sep 6 72.00 71
JN26-006 Lost Ace Sep 6 Sep 7 64.00 69
JN26-007 Lost Ace Sep 7 Sep 9 71.00 80
JN26-008 POW Sep 9 Sep 13 197.45 218
Total       1,390.9 1,464*

*Sample numbers include quality control samples (blanks, standards and duplicates).

Five holes were completed at the POW Zone and three holes at the Lost Ace Zone. Core cutting and sampling are continuing at site, with cutting of JN26-007 underway.

Assay Status

  • JN26-001 (341 samples) was shipped August 26, 2026 and received by Bureau Veritas the same day.
  • JN26-002 (227 samples) was shipped August 31, 2026 and received by Bureau Veritas the same day.
  • JN26-003 (217 samples) were shipped September 9, 2026 and submitted to Kamloops Actlabs since they could accommodate a rush analysis.

Samples from JN26-004 through JN26-008 are being prepared for subsequent dispatches. Assay results will be released as they are received, reviewed, and interpreted.

Riley Trimble, President and CEO of Aben Gold, commented: “Completing 1,390 metres across eight holes, above our original 1,300-metre plan, is a strong finish to the 2026 season at Justin. We drilled both POW and Lost Ace, and sent the first two holes into the lab earlier in the program, and have now sent JN26-003 on a rush basis. Our focus turns to receiving assays and using this new dataset to plan the next phase of work.”

The 2026 program was designed to test continuity and depth of gold-tungsten mineralization at the POW Zone and high-grade, structurally-controlled gold mineralization at Lost Ace. As previously disclosed, massive sulphides and ultraviolet indication of scheelite (WO₃) were observed in POW Zone core during the program. Visual observations are not a substitute for assay results.

Image 1 – JN26-003 140.02-148.52m Ultraviolet Light

Click here to view image

Milosz Mielniczuk, VP Exploration and Qualified Person of Aben Gold, commented: “We are thrilled to have completed the 2026 program safely and efficiently. I would like to extend a big thank you to the contractors who made this possible: Empire Drilling, Summit Air, Matrix, and Axiom. It was a pleasure working alongside you all, and we look forward to the 2027 season.”

Image 2 – Justin Camp August 2026
Click here to view image

Image 3 – Project Location and Target Zones

Click here to view image

About the Justin Gold-Tungsten Project

The Justin Project covers approximately 7,400 hectares and is 100% owned by Aben Gold. It is in the Tombstone Gold-Tungsten Belt and broader Tintina Gold Province of southeastern Yukon, adjacent to Seabridge Gold’s 3 Aces Project.

Historical drilling at the POW Zone includes 1.25 g/t Au over 60.0 metres, including 2.47 g/t Au over 21.0 metres, in JN11-009, and 2.52 g/t Au with 29.53 g/t Ag over 12.0 metres in JN11-010, with subsequent tungsten re-assays returning 0.25% WO₃ over the same 12.0 metre interval in JN11-010. See News Releases: October 16, 2014 and November 17, 2011.

Lost Ace is a separate high-grade gold target where historical trench sampling returned 20.8 g/t Au over 4.4 metres and 88.2 g/t Au over 1.0 metre. See News Release: January 14, 2019.

Qualified Person:

Milosz Mielniczuk, B.Sc. P.Geo., V.P. of Exploration for Aben Gold, has reviewed and approved the technical aspects of this news release and is the Qualified Person as defined by National Instrument 43-101.

About Aben Gold:

The Company’s goal is to increase shareholder value through new discoveries and developing exploration projects in geopolitically favourable jurisdictions.

X
LinkedIn

For further information on Aben Gold Corp. (TSX-V: ABM), visit our Company’s website at www.abengold.com.

ABEN GOLD CORP.

“Riley Trimble”
______________________
Riley Trimble
President & CEO

For further information contact:
Aben Gold Corp.
Riley Trimble, President & CEO
Telephone: 604-639-3852
Facsimile: 604-687-3119
Email: info@abengold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements.  Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedarplus.ca for further information.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.